Know Your ADCs: Nursing Perspectives on Antibody-Drug Conjugates Targeting TROP-2 in Solid Tumors

Get up to date on TROP2-targeted ADCs across tumor types with this comprehensive nursing program featuring an on-demand webcast and downloadable slidesets from a live symposium along with an expert-authored commentary.

Share

Program Content

Activities

TROP2 ADC Overview
Antibody‒Drug Conjugates and Their Role in TROP2-Expressing Tumors
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 28, 2023

TROP2 ADC Efficacy
Clinical Data on TROP2-Targeting ADCs in Breast, Urothelial, and Lung Cancers
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 28, 2023

TROP2 ADC Toxicity
Identification and Management of Adverse Events With TROP2-Targeting ADCs
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 28, 2023

Activities

Nursing Perspectives TROP2 ADCs
Know Your ADCs: Nursing Perspectives on Antibody–Drug Conjugates Targeting TROP2 in Solid Tumors
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 22, 2023

Expires: June 21, 2024

Activities

TROP2 ADCs for Oncology Nurses
TROP-2–Targeting Antibody–Drug Conjugates: Perspectives for the Oncology Nurse Specialist
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 26, 2023

Faculty

cover img faculity

Elise Hitron, MSN, FNP-C

Nurse Practitioner
Phase I Clinical Trials at Winship Cancer Institute
Atlanta, Georgia

cover img faculity

Srigowri Kota, MSN, BA, APRN, AGNP-C, OCN

Nurse Practitioner
Department of Genitourinary Medical Oncology
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey

cover img faculity

Neelima Vidula, MD

Assistant Professor of Medicine
Harvard Medical School
Attending Physician
Department of Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Gilead Sciences, Inc. 

Gilead Sciences, Inc.